Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: Points of pathophysiological commonality with mood disorders?

Advances in Therapy

Volumn 27, Issue 2, 2010, Pages 63-80

  McIntyre, Roger S ^c   Kenna, Heather A ^b   Nguyen, Ha T ^a   Law, Candy W Y ^a   Sultan, Farah ^a   Woldeyohannes, Hanna O ^a   Alsuwaidan, Mohammad T ^a   Soczynska, Joanna K ^a   Adams, Amanda K ^a   Cheng, Jenny S H ^a   Lourenco, Maria ^a   Kennedy, Sidney H ^a   Rasgon, Natalie L ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c NONE

Author keywords

Amygdala; Brain; Diabetes mellitus; Hippocampus; Mood disorders; Morphometric; MRI; Neurocognitive deficits

Indexed keywords

GLUCOCORTICOID; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR SUBSTRATE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN SHC; RAS PROTEIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

AMYGDALOID NUCLEUS; APOPTOSIS; BRAIN ATROPHY; BRAIN DYSFUNCTION; BRAIN INFARCTION; BRAIN REGION; BRAIN SIZE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC ANGIOPATHY; DIFFUSION TENSOR IMAGING; DISEASE MODEL; ENZYME INACTIVATION; HIPPOCAMPUS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTHESIS; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LEUKOARAIOSIS; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; QUALITY CONTROL; RECEPTOR UPREGULATION; REVIEW; SAMPLE SIZE; WECHSLER INTELLIGENCE SCALE;

AGE FACTORS; BRAIN; BRAIN DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MOOD DISORDERS;

EID: 77953020271     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0011-z     Document Type: Review

References (44)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:S5-S10.
2. Reske-Nielsen E, Lundbaek K. Diabetic encephalopathy. Diffuse and focal lesions of the brain in long-term diabetes. Acta Neurol Scand. 1963;39(suppl. 4):90.
3. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann Clin Psychiatry. 2007;19:257-264.
4. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169-178.
5. Lustman PJ, Griffith LS, Clouse RE, Cryer PE. Psychiatric illness in diabetes mellitus. Relationship to symptoms and glucose control. J Nerv Ment Dis. 1986;174:736-742.
6. Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. J Gerontol A Biol Sci Med Sci. 2004;59:178-183.
7. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry. 2003;54:200-207.
8. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105-122.
9. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord. 2008;10:1-37.
10. Rasgon NL, Kenna HA. Insulin resistance in depressive disorders and Alzheimer's disease: revisiting the missing link hypothesis. Neurobiol Aging. 2005;26(suppl. 1):103-107.
11. Soininen H, Puranen M, Helkala EL, Laakso M, Riekkinen PJ. Diabetes mellitus and brain atrophy: a computed tomography study in an elderly population. Neurobiol Aging. 1992;13:717-721.
12. Araki Y, Nomura M, Tanaka H, et al. MRI of the brain in diabetes mellitus. Neuroradiology. 1994;36:101-103.
13. Convit A, De Leon MJ, Tarshish C, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging. 1997;18:131-138.
14. Perros P, Deary IJ, Sellar RJ, Best JJ, Frier BM. Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. Diabetes Care. 1997;20:1013-1018.
15. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003;46:1604-1610.
16. Ferguson SC, Blane A, Perros P, et al. Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes. 2003;52:149-156.
17. Ferguson SC, Blane A, Wardlaw J, et al. Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care. 2005;28:1431-1437.
18. Lobnig BM, Kromeke O, Optenhostert-Porst C, Wolf OT. Hippocampal volume and cognitive performance in long-standing type 1 diabetic patients without macrovascular complications. Diabet Med. 2006;23:32-39.
19. Musen G, Lyoo IK, Sparks CR, et al. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes. 2006;55:326- 333.
20. Wessels AM, Simsek S, Remijnse PL, et al. Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia. 2006;49:2474-2480.
21. Wessels AM, Rombouts SA, Remijnse PL, et al. Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. Diabetologia. 2007;50:1763-1769.
22. Perantie DC, Wu J, Koller JM, et al. Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care. 2007;30:2331-2337.
23. Jongen C, van der GJ, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia. 2007;50:1509-1516.
24. Kumar R, Anstey KJ, Cherbuin N, Wen W, Sachdev PS. Association of type 2 diabetes with depression, brain atrophy, and reduced fine motor speed in a 60- to 64-year-old community sample. Am J Geriatr Psychiatry. 2008;16:989-998.
25. Kodl CT, Franc DT, Rao JP, et al. Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes. 2008;57:3083-3089.
26. Haroon E, Watari K, Thomas A, et al. Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients. Psychiatry Res. 2009;171:10-19.
27. Northam EA, Rankins D, Lin A, et al. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care. 2009;32:445-450.
28. Auer RN, Siesjo BK. Hypoglycaemia: brain neurochemistry and neuropathology. Baillieres Clin Endocrinol Metab. 1993;7:611-625.
29. Deary IJ, Crawford JR, Hepburn DA, Langan SJ, Blackmore LM, Frier BM. Severe hypoglycemia and intelligence in adult patients with insulin-treated diabetes. Diabetes. 1993;42:341-344.
30. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:4766-4770.
31. van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol. 2006;79:205-221.
32. Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev. 2005;4:195-212.
33. Fernandez S, Fernandez AM, Lopez-Lopez C, Torres-Aleman I. Emerging roles of insulin-like growth factor-I in the adult brain. Growth Horm IGF Res. 2007;17:89-95.
34. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317-329.
35. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004;56:819-824.
36. Paris D, Town T, Parker T, Humphrey J, Mullan M. beta-Amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP-elevating agents. Ann N Y Acad Sci. 2000;903:446-450.
37. Rosenberg PB. Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatry. 2005;17:503-514.
38. Laws SM, Perneczky R, Wagenpfeil S, et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat. 2005;26:29-35.
39. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 2006;8:25.
40. Collino M, Aragno M, Mastrocola R, et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol. 2006;530:70-80.
41. Lopes JP, Oliveira SM, Soares FJ. [Oxidative stress and its effects on insulin resistance and pancreatic beta-cells dysfunction: relationship with type 2 diabetes mellitus complications]. Acta Med Port. 2008;21:293-302. Article in Portuguese.
42. Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57:470-484.
43. McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res. 2002;53:883-890.
44. Wrighten SA, Piroli GG, Grillo CA, Reagan LP. A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta. 2009;1792:444-453.